LeadershipAdvocacy & Gov't AffairsHistoryCareers at Joslin
Newly DiagnosedManaging DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsJoslin Clinical ResearchInfo for Healthcare ProfessionalsJoslin Clinical Guidelines
Adult ClinicYoung Adult Transition CarePediatricsEye CareWeight Management ProgramsDO ITMental Health & CounselingReferring PhysiciansBillingAsian ClinicLatino Diabetes InitiativeAbout Joslin ResearchVolunteer for Clinical Research StudiesInfo for Healthcare ProfessionalsClinical Guidelines
Directory of Joslin InvestigatorsDiabetes Research Center Alumni ConnectionVolunteer for Clinical Research Studies
Media RelationsNews ReleasesInside Joslin
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCause MarketingCommercialization and VenturesHealthcare Professionals
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

Thaddeus Dryja, M.D.

Dr. Dryja specializes in ophthalmology and is recognized for his 1986 discovery of the Rb tumor suppressor gene, mutations in which lead to a cancer of the eye known as retinoblastoma. He was elected to the National Academy of Sciences in 1996, and currently is Professor of Ophthalmology at Harvard Medical School. Dr. Dryja also leads a research group at the Massachusetts Eye and Ear Infirmary in Boston, Massachusetts.

Page last updated: April 18, 2014